The Motley FoolPublished 2026-10-17
“Motley Fool CEO Tom Gardner Reveals 8 Stocks He'd Buy Now”
$ASNDBullish
ASND is a long-term buy: its gradual-release drug platform offers major long-term growth and potential partnerships, including with Novo Nordisk, while strong financial management, $600 million cash, high margins and high returns on capital make it a wonderful company.
The first company is Ascendis Pharmaceuticals, and its trading symbol is ASND. It seems no one has heard of her. The company is headquartered in Copenhagen, Denmark. So, the first thing I would say is that it's great to have some investments outside of the United States .
The second thing is that it is a biotechnology company that targets rare hormone disorders.